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DOI 10.1016/j.ccr.2012.02.009SUMMARYMLN4924 is an investigational small-molecule inhibitor of NEDD8-activating enzyme (NAE) in clinical trials for
the treatment of cancer. MLN4924 is a mechanism-based inhibitor, with enzyme inhibition occurring through
the formation of a tight-binding NEDD8-MLN4924 adduct. In cell and xenograft models of cancer, we iden-
tified treatment-emergent heterozygous mutations in the adenosine triphosphate binding pocket and
NEDD8-binding cleft of NAEb as the primary mechanism of resistance to MLN4924. Biochemical analyses
of NAEb mutants revealed slower rates of adduct formation and reduced adduct affinity for the mutant
enzymes. A compound with tighter binding properties was able to potently inhibit mutant enzymes in cells.
These data provide rationales for patient selection and the development of next-generation NAE inhibitors
designed to overcome treatment-emergent NAEb mutations.INTRODUCTION
Targeting ubiquitin and ubiquitin-like protein (UBL) pathways
with small molecule inhibitors is an emerging therapeutic
strategy for a variety of diseases (Schulman and Harper, 2009).
Of the seventeen identified UBLs, many play critical roles in
the modulation of cancer cell growth and survival pathways
through their control of protein homeostasis (Nalepa et al.,
2006). Our efforts to inhibit enzymes that control UBL conjuga-
tion led to the identification of MLN4924, an investigational
small molecule inhibitor of the NEDD8-activating enzyme (NAE;
Soucy et al., 2009a). The inhibition of NAE by MLN4924 results
in the inactivation of a family of E3 ubiquitin ligases, which
results in DNA re-replication and inhibition of nuclear factor
(NF)-kB signaling, leading to cancer cell death (Milhollen et al.,
2010, 2011). MLN4924 is currently in clinical trials and has
shown clinical activity in some solid tumor and hematologic
malignancies (Wang et al., 2011). Therefore, we sought to defineSignificance
There are numerous examples of target-based mutations lead
imatinib). This has enabled drug discovery efforts resulting in th
itors. As a result of this trend, predicting and responding to res
and to promptly meeting the needs of patients. Compelled by
we sought to preemptively define the landscape of resistance
NAEb. If resistance occurs in the clinic, these findings will acc
insights into the development of second-generation NAE inhib
388 Cancer Cell 21, 388–401, March 20, 2012 ª2012 Elsevier Inc.mechanisms of resistance to MLN4924 in preclinical models of
cancer.
The inhibition of NAE by MLN4924 occurs through the forma-
tion of a NEDD8-MLN4924 covalent adduct resembling NEDD8-
AMP, a process that requires NAE catalytic activity (Brownell
et al., 2010). Importantly, the NEDD8-MLN4924 adduct is a tight
binding inhibitor of NAE, and it has been proposed that the tight
binding nature of the inhibitor-protein adduct is crucial for
MLN4924 potency (Brownell et al., 2010). The best characterized
substrates of NEDD8 conjugation are the cullin scaffold proteins
of the cullin-RING ligase (CRL) complexes, which control the
ubiquitination and proteasomal destruction of numerous
cancer-relevant proteins (Soucy et al., 2009b; Watson et al.,
2011). Thus, inhibition of NAE and NEDD8 conjugation by
MLN4924 leads to the inhibition of CRL activity and perturbation
of cellular protein homeostasis (Soucy et al., 2009a). The evalu-
ation of MLN4924 in cellular and tumor xenograft studies has
revealed two distinct mechanisms of action. The first is theing to treatment-emergent resistance in oncology (e.g., with
e identification of superior and/or second-generation inhib-
istance is critical to the full exploitation of an oncology target
clinical activity of MLN4924 in acute myelogenous leukemia,
mechanisms and identified treatment-induced mutations of
elerate our assessment of the molecular cause and provide
itors.
Figure 1. MLN4924-Resistant HCT-116 Clones Show Reduced
Sensitivity to MLN4924
HCT-116 WT cells and resistant clones were treated with DMSO or various
concentrations of MLN4924 for 96 hr, and cell viability was assessed with an
ATPlite assay. Data shown are mean ± standard deviation (n = 3 experiments).
See also Figure S1.
Table 1. HeterozygousMutations inNAEbDetected in MLN4924-
Resistant HCT-116, NCI-H460, and Calu-6 clones
Cell Line
NAEb Status
Sanger Sequenom
HCT-116 parental WT WT
HCT-116.1 A171T A171T
HCT-116.2 A171T A171T
HCT-116.3 A171T A171T
HCT-116.4 C324Y C324Y
HCT-116.5 G201V G201V
NCI-H460 parental WT WT
NCI-H460.1 E204K E204K
NCI-H460.2 A171D A171D
Calu-6 parental WT WT
Calu-6.1 N209K N209K
See also Figure S2 and Tables S1, S2, and S4.
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A Resistance Mechanism for NAE Inhibitioninduction of DNA re-replication, DNA damage, and cell death
through MLN4924-mediated dysregulation of the CRL1SKP2
and CRL4DDB1 substrate CDT1 (Milhollen et al., 2011). It
has been shown that p53 status does not impact the induc-
tion of DNA re-replication but may make cells more prone to
undergo apoptosis or senescence, depending on the appro-
priate genetic background (Milhollen et al., 2011; Lin et al.,
2010a, 2010b). The second mechanism is the inhibition of
NF-kB pathway activity in NF-kB-dependent diffuse large B
cell lymphomas (DLBCL), primarily through dysregulation of
CRL1bTRCP-mediated turnover of phosphorylated IkBa (Milhollen
et al., 2010). In addition, preclinical models of acute myeloge-
nous leukemia (AML) are sensitive to MLN4924 inhibition in
both cell lines and primary patient blasts through mechanisms
related to CDT1 dysregulation, NF-kB inhibition, and induction
of reactive oxygen species (Swords et al., 2010). These data
highlight the therapeutic potential of MLN4924 in a diverse set
of preclinical cancer models.
MLN4924 is currently undergoing phase I clinical testing in
a variety of solid tumor and hematological malignancies (Wang
et al., 2011). Clinical activity has been described in patients
with AML with reports of 3 of 15 patients achieving a complete
response on MLN4924 therapy (Wang et al., 2011). With initial
signs of clinical activity with a pathway inhibitor, it is increasingly
important to identify potential mediators of resistance in preclin-
ical models that can be predictive of clinical observations
(Sellers, 2011). Thus, we utilized cellular and tumor xenograft
models of cancer as an approach to study acquired resistance
to MLN4924.
In this report we describe the emergence of heterozygous
mutations in the NAEb (UBA3) subunit of NAE in cell lines
and xenograft models of cancer following selection pressure
with MLN4924. We evaluate how such mutations may reduce
compound potency and present evidence in cells and xeno-
grafts regarding pathway inhibition, levels of NAEb-bound
NEDD8-MLN4924 adduct, and recovery of pathway activity
following inhibition. Finally, we investigate a pan-E1 inhibitor
with tighter binding properties and its ability to inhibit NEDD8
conjugation in MLN4924-resistant cells carrying a mutation in
NAEb.RESULTS
Clonal Selection of Tumor Cell Lines that Are Resistant
to MLN4924 Show Reduced Pathway Inhibition In Vitro
and Contain a Mutation in NAEb
Three solid tumor cell lines (HCT-116 colorectal, NCI-H460 lung,
and Calu-6 lung) that have been shown to undergo DNA re-
replication in response to NAE inhibition (Soucy et al., 2009a)
were chosen to study potential mechanisms of resistance
to MLN4924. These cell lines have differential sensitivity to
MLN4924-induced cytotoxicity, with EC50 values (cell viability
assay) of 46, 80, and 1070 nM for HCT-116, Calu-6, and NCI-
H460 cells, respectively. Cells were exposed to high concentra-
tions of MLN4924 (REC90 concentrations) for four days, which
resulted in almost-complete cell kill, and five resistant clones
were obtained for HCT-116 cells. One HCT-116 clone was found
to be 10-fold less sensitive to MLN4924, and four had EC50
values greater than 3 mM (Figure 1). Similarly, one Calu-6 clone
and two NCI-H460 clones were isolated and found to have
EC50 values of >10 mM (Figure S1 available online). The
MLN4924-resistant HCT-116 cell clones remained sensitive to
other chemotherapies (bortezomib, doxorubicin, and SN-38;
Figure S1), suggesting that the resistance mechanism is not
a shared mechanism with other agents.
To determine whether changes in the NEDD8 pathway may
explain the resistance to MLN4924, cells were evaluated
for changes in gene transcript levels or the presence of DNA
mutations in NAEb, NAE1, NEDD8, COPS5, or UBC12, the
primary E2 for neddylation. No substantial changes were found
in mRNA levels of neddylation pathway genes (Figure S2A).
Changes were observed in mRNA levels of adenosine triphos-
phate (ATP)-binding cassette-transporter proteins; however,
MLN4924 activity was unaffected by co-incubation with drug
efflux inhibitors (Figure S2B). DNA sequencing revealed no treat-
ment-emergent DNA mutations in NAE1, UBC12, COPS5, or
NEDD8; however, heterozygous mutations in NAEb were
detected by Sanger sequencing in all resistant cell lines (Tables 1
and S1). These mutations were confirmed using additional
mass spectrometry-based and next-generation sequencingCancer Cell 21, 388–401, March 20, 2012 ª2012 Elsevier Inc. 389
Figure 2. MLN4924-Resistant HCT-116 Clones Show Reduced NEDD8 Pathway Inhibition and Contain a Heterozygous Mutation in NAEb
HCT-116 WT cells and resistant clones were treated with DMSO or various concentrations of MLN4924 for 4 hr. Western blots were probed for NEDD8-cullin,
CUL1, NEDD8-NAEb, NEDD8-UBC12, NEDD8-MLN4924 adduct, CDT1, NRF2, and tubulin. See also Figure S2.
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be consistent with modification of MLN4924 binding in the
nucleotide binding pocket (A171T and A171D) or in affecting
the ability of NEDD8 to bind to NAEb (G201V, E204K, N209K,
and C324Y). Of note, a heterozygous mutation in NEDD8 (I44T)
was detected in wild-type HCT-116 cells, which was maintained
in the resistant clones. However, the activity of this NEDD8
mutant was identical to wild-type NEDD8 in biochemical assays
(data not shown).
Pathway analysis by western blotting was performed following
a 4 hr incubation of compound to assess the effect of MLN4924
on the NEDD8 pathway in the resistant clones. Two HCT-116
clones were selected for analysis (A171T and G201V), and
a reduced effect of inhibition of NEDD8 conjugation to NAEb,
UBC12, and the cullin proteins was demonstrated when
compared to wild-type cells (Figure 2). The reduced effect on
NAE inhibition was confirmed by a reduced accumulation of
two CRL substrates, NRF2 and CDT1 (Figure 2). As expected,
NEDD8-MLN4924 adduct could still be detected in the resistant
cell lines, since there is still one wild-type copy of NAEb.
In addition, the steady-state neddylation levels of the cullins,
and specifically cullin-1 (CUL1), are similar in the three cell
lines, and the inhibition of CUL1 neddylation reflects that of the
total cullins (Figure 2). MLN4924 induces DNA re-replication
in HCT-116 cells (Milhollen et al., 2011), yet the cell-cycle
distribution of HCT-116-resistant A171T and G201V clones
treated with MLN4924 is not significantly altered, consistent
with their insensitivity to MLN4924 (Figure S3). Similar effects
of reduced potency of MLN4924 on the neddylation pathway
and CRL substrate accumulation were observed in NCI-H460
A171D clone (Figure S3). Reduced pathway inhibition was also
observed in the Calu-6 N209K clone, but this was not as marked
as in other resistant clones (Figure S3). These data demonstrate
that in vitro-derived MLN4924-resistant cell lines contain hetero-
zygous mutations in NAEb and are, as a result, less sensitive to
NAE inhibition.390 Cancer Cell 21, 388–401, March 20, 2012 ª2012 Elsevier Inc.HCT-116 Xenografts Become Resistant to Antitumor
Effects of MLN4924, Demonstrate Reduced
Pharmacodynamic Effects, and Contain Mutations
in NAEb
HCT-116 cells were grown as subcutaneous xenografts in immu-
nocompromised rats and then subcutaneously treated with the
maximum tolerated dose of MLN4924 (150 mg/kg) on a dosing
schedule of days 1, 4, 8, and 11 of a 21-day therapy cycle. Impor-
tantly, this regimen was chosen as it is currently being utilized in
phase I clinical studies of MLN4924 in solid and hematologic
malignancies. After the first cycle of MLN4924, tumor regres-
sions were observed that were maintained through most of the
second cycle of treatment (Figure 3A). However, during cycle
3, ten of eleven tumors began to regrow, even in the presence
of MLN4924 (Figure 3A). Tumors were harvested at the end of
treatment and the nucleic acid sequence of NAEbwas analyzed.
Eight of ten tumors were found to contain a heterozygous muta-
tion at A171T of NAEb (Figure 3A and Table S2). Interestingly, in
two tumors, more than one mutation was detected (A171T/
E204K and A171T/A171D/Y228H, respectively), indicating that
multiple clonesmay emerge within a tumor population. Nomuta-
tions were detected in NAE1, COPS5, or UBC12, and the I44T
mutation within NEDD8 was detected, consistent with cells
grown in vitro.
To confirm that the tumors were now stably resistant to
MLN4924, one xenograft with an A171T mutation was retrans-
planted into nude rats. The antitumor activity of MLN4924 was
dramatically reduced compared to wild-type xenografts; one
cycle of MLN4924 150 mg/kg (days 1, 4, 8, and 11) inhibited
tumor growth by only 38% compared to 94% (including tumor
regressions) that were observed in wild-type xenografts (Fig-
ure 3B). The A171T NAEbmutation was still present in this resis-
tant xenograft model as confirmed by both Sanger and Seque-
nom methodologies. Pharmacodynamic analysis of NEDD8
pathway inhibition by MLN4924 in HCT-116 wild-type and
A171T-resistant xenografts was conducted following a single
Figure 3. HCT-116 Xenograft-Bearing NudeRats BecomeRefractory toMLN4924 Treatment, Contain a HeterozygousMutation in NAEb, and
Are Resistant to Retreatment
(A) Immunocompromised nude rats bearing HCT-116 xenografts were administered MLN4924 150 mg/kg on days 1, 4, 8, and 11 of a 21-day cycle for three
cycles. Tumors were harvested at the end of treatment for analysis, and the mutational status of NAEb was determined. Data shown are mean ± standard error
(n = 10) for vehicle group.
(B) A tumor containing an alanine 171 to threonine mutation was re-established in nude rats and treated with MLN4924 150 mg/kg on days 1, 4, 8, and 11 of
a 21-day cycle. The response of WT (parental) tumors is included on the graph for comparison. Data shown are mean ± standard error (n = 10).
(C–F) Nude rats bearing HCT-116 parental or A171T xenografts were administered a single dose of 150mg/kgMLN4924 and tumorswere excised at the indicated
times and measured for (C) NEDD8-cullin conjugate levels by western blotting; (D) CDT1 levels by immunohistochemistry; (E) cleaved caspase-3 levels by
immunohistochemistry; and (F) NEDD8-MLN4924 adduct levels by mass spectrometry. Data shown are mean ± standard deviation (n = 3 replicates). See also
Table S2 and Figure S4.
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cullin levels occurred as early as 1 hr postdose in HCT-116
wild-type xenografts compared to 8 hr postdose in the A171T-
resistantmodel (Figures 3C andS4A). In agreement with reduced
effects on NEDD8-cullin levels in HCT-116 A171T cells was a
reduction in CDT1 levels (Figures 3D and S4B), apoptosis asmeasured by cleaved caspase-3 (Figure 3E and S4C), and
NEDD8-MLN4924 adduct (Figure 3F) compared to HCT-116
wild-type xenografts. These data demonstrate that tumor xeno-
grafts treated with a clinically relevant dosing schedule can
acquire resistance toMLN4924 that is associated withmutations
in NAEb.Cancer Cell 21, 388–401, March 20, 2012 ª2012 Elsevier Inc. 391
Figure 4. Acute Myelogenous Leukemia and Diffuse Large B Cell Lymphoma Xenograft-Bearing NudeMice Become Refractory to MLN4924
Treatment, Contain a Heterozygous Mutation in NAEb, and Are Resistant to Retreatment
(A) CB.17 SCID mice bearing THP-1 AML xenografts were administered MLN4924 90 mg/kg BID on days 1, 4, 8, 11, 15, and 18 of a 21-day cycle for up to five
cycles. Tumors were harvested at the end of treatment for analysis, and the mutational status of NAEb was determined. Data shown are mean ± standard error
(n = 10) for vehicle group.
(B) A tumor containing an alanine 171 to threonine mutation was re-established in CB.17 SCID mice and treated with MLN4924 90 mg/kg BID on days 1, 4, 8, 11,
15, and 18 of a 21-day cycle. The response of WT (parental) tumors is included on the graph for comparison. Data shown are mean ± standard error (n = 10).
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in AML and DLBCL Xenografts
MLN4924 has shown clinical activity in patients with AML (Wang
et al., 2011). Therefore, we utilized THP-1 cells, a relevant subcu-
taneous AML preclinical model, to determine whether resistance
to MLN4924 could be driven by NAEb mutations. The subcuta-
neous model was utilized to facilitate harvesting tumors for
subsequent analysis. On a clinically relevant schedule,
MLN4924 was administered to SCID mice bearing THP-1 xeno-
grafts (90 mg/kg BID, twice-weekly), and uniform tumor regres-
sions were observed (Figure 4A). Six of ten THP-1 xenografts
regrew during the MLN4924 treatment period and were har-
vested for analysis. Three of these THP-1 xenografts contained
a heterozygous mutation in NAEb at A171T, one contained
a heterozygous mutation at N209D, and the remaining two
were wild-type for NAEb so may be refractory through an alter-
nate mechanism (Figure 4A and Table S2). Again, no mutations
were observed in NAE1, COPS5, UBC12, or NEDD8. One
A171T THP-1 xenograft was successfully re-established in
SCID mice and shown to be resistant to MLN4924 when dosed
at 90 mg/kg BID twice-weekly (Figure 4B). Pharmacodynamic
evaluation in THP-1 A171T xenografts showed that MLN4924
produced minimal inhibition of NEDD8-cullin levels (Figures 4C
and S5A), resulting in a reduced elevation of the CRL substrate
pIkBa (Figures 4D and S5B) and a failure to activate apoptosis
(Figures 4E and S5C) in comparison to THP-1 wild-type
xenografts.
We have previously shown that activated B cell-like (ABC-)
DLBCLmay be particularly sensitive to MLN4924 through inhibi-
tion of constitutively active NF-kB signaling (Milhollen et al.,
2010). To determine whether resistance to MLN4924 through
NAEb mutations occurs in models in which re-replication does
not drive the terminal outcome, we followed OCI-Ly10 xeno-
graft-bearing mice and administered MLN4924 (90 mg/kg BID,
twice-weekly) for more than 100 days. Consistent with our
previous findings, MLN4924 induced tumor regressions in the
OCI-Ly10 model (Figure 4F). Only one of ten tumors regrew
during therapy, and subsequent analysis revealed a heterozy-
gous mutation in NAEb at E204G. The tumor was re-implanted
and was, as with the other re-introduced resistant tumors, resis-
tant to MLN4924 treatment at 90 mg/kg BID (Figure 4G). These
data demonstrate that, regardless of the MLN4924-dependent
terminal outcome or genetic background, certain NAEb muta-
tions can drive resistance to MLN4924.
Mutations in the Nucleotide Binding Pocket and NEDD8
Binding Cleft of NAEb Affect MLN4924 Adduct
Formation and Dissociation from NAEb
TheNAEbmutations that have been detected inMLN4924-resis-
tant cells derived in tissue culture or in vivo occur in two areas of(C–E) CB.17 SCID mice bearing THP-1 parental or A171T xenografts were admi
indicated times andmeasured for (C) NEDD8-cullin conjugate levels by western bl
immunohistochemistry. Data shown are mean ± standard deviation (n = 3 replic
istered MLN4924 90 mg/kg BID on days 1, 4, 8, 11, 15, and 18 of a 21-day cycle fo
and the mutational status of NAEb was determined. Data shown are mean ± sta
(G) A tumor containing a glutamic acid 204 to glycine mutation was re-established
11, 15, and 18 of a 21-day cycle. The response of WT (parental) tumors is include
See also Table S2 and Figure S5.the gene, the nucleotide binding pocket at Alanine 171 and at
various residues that are within or close to the NEDD8 binding
cleft (Figures 5A and 5B). Mutations at Alanine 171 appear to
be a ‘‘hotspot,’’ since approximately two-thirds of the mutations
detected lie at this residue (Figure 5A). Structural renderings of
the A171T and A171D mutants suggest that decreased potency
of MLN4924 could occur through a clash with the indane group
of MLN4924 and the bulkier threonine or aspartic acid residue in
mutant NAEb (Figure 5B). In contrast, mutations found in the
NEDD8 binding region of NAEb are hypothesized to affect the
affinity of NEDD8 and in turn the NEDD8-MLN4924 adduct (Fig-
ure 5B). To understand the biochemical consequences of muta-
tions in these regions, recombinant enzymes expressing A171T,
A171D, N209K, E204K, or G201Vwere constructed as represen-
tative of the two classes of mutations (Table 2). Structural
modeling of A171T or A171D did not predict an effect on ATP
binding, yet these mutations did result in weaker affinity for
ATP. However, the titration profile and affinity for NEDD8 was
largely unaffected by mutations to A171 (Table 2 and Figure S6).
In contrast, mutations in the NEDD8 binding cleft (G201V and
E204K) resulted in a shift in the NEDD8 titration profile, which
attributes to a concomitant increase in the KM for NEDD8 (Table
2 and Figure S6). Neither of these NEDD8 binding cleft mutations
had much effect on the KM for ATP. Interestingly, a mutation at
G201V resulted in an increase in both the KM for ATP and
NEDD8, whereas the KM for PPi was unaffected by any of these
mutations (Table 2). In addition, other than the A171D mutant,
the catalytic rate (kcat) of the NAE reaction is not severely
affected by any of these mutations; in fact, it appears that the
G201V mutant is more catalytically active than is the wild-type
enzyme (Table 2).
We have previously demonstrated that MLN4924 inhibits the
NEDD8-NAEb thioester form of NAE by occupying the nucleo-
tide binding site and forming a covalent adduct between
NEDD8 and MLN4924 (Brownell et al., 2010). To determine the
effect of inhibitory potency of MLN4924 against wild-type and
mutant enzymes, the PPi-ATP assay was performed using
a concentration of 1 mM ATP. Interestingly, the A171T mutant
was still capable of being inhibited by MLN4924 with only
a modest 2-fold decrease in potency compared to wild-type
enzyme (Table 2).MLN4924did not inhibit A171Dup to a concen-
tration of 100 mM, suggesting that the bulkier aspartic acid
residue impedes MLN4924 binding in the nucleotide binding
pocket. MLN4924 was approximately 10-fold less active against
the NEDD8 binding cleft mutants compared to wild-type
enzyme. Compound 1, a structurally similar N6-substituted
adenosine sulfamate, was used for comparison with MLN4924
(Brownell et al., 2010). The potency of Compound 1 decreased
7-fold versus the A171T mutant and 17,000-fold versus the
A171D mutant (Table 2). A noticeable decrease in potency wasnistered a single dose of MLN4924 90 mg/kg and tumors were excised at the
otting; (D) pIkBa levels by western blotting; and (E) cleaved caspase-3 levels by
ates). (F) CB.17 SCID mice bearing OCI-Ly10 DLBCL xenografts were admin-
r up to five cycles. Tumors were harvested at the end of treatment for analysis,
ndard error (n = 10) for vehicle group.
in CB.17 SCID mice and treated with MLN4924 90 mg/kg BID on days 1, 4, 8,
d on the graph for comparison. Data shown are mean ± standard error (n = 10).
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Figure 5. NAEb Mutants Located in ATP Binding Pocket and NEDD8-Binding Cleft Lead to Faster Recovery from Enzyme Inhibition
(A) Schematic representation of location and frequency of NAEb mutations detected in cells and xenografts.
(B) Crystal structure of NAE with NEDD8-MLN4924 adduct bound (PDB entry 3GZN; Brownell et al., 2010), highlighting NAEb mutations.
(C) NAEb mutants were inhibited with MLN4294 or compound 1 and purified, and complexes were added to transthiolation reaction containing 1 mM ATP to
measure recovery of enzyme activity. Data shown are the mean of four replicates. See also Table S3.
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Table 2. Biochemical Characterization of NAEb Mutants.
NAEb Enzyme KM ATP (mM) KM NEDD8 (mM) KM PPi (mM) kcat (s
1) MLN4924 IC50 (mM) Compound 1 IC50 (mM)
WT 88 ± 3 0.044 ± 0.024 22 ± 2 1.2 ± 0.2 0.049 ± 0.011 0.0041 ± 0.0002
A171T 600 ± 30 0.080 ± 0.018 22 ± 2 1.5 ± 0.4 0.10 ± 0.026 0.030 ± 0.002
A171D 1,900 ± 20 0.016 ± 0.0037 10 ± 2 0.33 ± 0.08 >100 70 ± 20
N209K 31 ± 1 0.43 ± 0.081 24 ± 2 2.0 ± 0.1 0.78 ± 0.16 0.076 ± 0.005
E204K 21 ± 1 0.48 ± 0.053 18 ± 1 1.3 ± 0.5 1.6 ± 0.20 0.17 ± 0.005
G201V 820 ± 36 3.5 ± 0.22 10 ± 1 3.7 ± 0.5 0.51 ± 0.057 0.0057 ± 0.0006
Several NAEbmutants were characterized in the pyrophosphate exchange assay and analyzed for parameters of KM for ATP, NEDD8, PPi, and cata-
lytic activity. The KM for each substrate was determined by titrating each substrate into the PPi-ATP assay and fitting the average of three replicates to
the standard Michaelis-Menten equation, y = Vmax* [S] / KM + [S], where y is PPi-ATP activity. The standard error was extrapolated from the fit. The kcat
for each enzyme using three replicates was determined under optimal conditions (saturating ATP, PPi, and peak [NEDD8]) and using an [a-32P]-ATP
standard curve. Each kcat value represents the average and standard deviations of duplicates experiments. NAEb mutants were tested in the pyro-
phosphate exchange using 1 mM ATP and measured for potency with MLN4924 and Compound 1. IC50 curves using the average of three replicates
were fit using a sigmoidal logistics 3-parameter equation, y = a / (1+([I]/IC50)
b, where y is% inhibition, a is amplitude, and b is hill slope. Each IC50 value
represents the average and standard deviations of duplicate experiments. See also Figure S6.
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mutants.
Since in vitro IC50s of enzyme inhibition did not fully explain the
resistance to MLN4924 observed, further compound character-
ization was performed to evaluate the rates of enzyme inactiva-
tion and the reversibility of compound inhibition. A171D NAEb
mutant was not used in these studies, because it was completely
insensitive to MLN4924 inhibition. Enzyme-inhibitor complexes,
NEDD8-MLN4924 or NEDD8-Compound 1, were pre-formed on
the enzyme, purified, and added to a UBC12 transthiolation
reaction to measure the recovery of enzyme activity (Figure 5C).
As previously reported, NEDD8-MLN4924 was a tight-binding
inhibitor of wild-type NAEb with enzyme activity, recovering to
approximately 30% of dimethylsulfoxide (DMSO) control levels
by 240 min. In contrast, the recovery of enzymatic activity
following MLN4924 inhibition was similar to that of the DMSO
control for A171T, N209K, E204K, and G201V mutants. These
data indicate that although the NEDD8-MLN4924 adduct is
formed by the mutant enzymes, it is no longer a tight-binding
inhibitor. The NEDD8-Compound 1 adduct binds more tightly
to wild-type NAEb than the NEDD8-MLN4924 adduct, with no
discernible recovery of enzymatic activity at 240 min (Figure 5C).
In addition, the NEDD8-Compound 1 adduct appears to be
a tighter binder of all mutant NAE enzymes, suggesting that
Compound 1 may be a more potent inhibitor of mutant enzyme
in cells compared to MLN4924.
The rate of enzyme inactivation by MLN4924 for both A171T
and N209K mutants was also dramatically slower compared to
wild-type as opposed to Compound 1, for which the rate of
wild-type and mutant enzyme inactivation was more rapid than
MLN4924 (Table S3). These data provide a rationale for explain-
ing the resistance that is conferred by mutations in NAEb,
namely, the slower rate of inactivation and faster off-rate of the
NEDD8-MLN4294 adduct.
Cells Containing Mutations in NAEb Form Lower Levels
of NEDD8-MLN4924 Adduct and Show Increased
Recovery of Pathway Activity
HCT-116 mutant cells lines (A171T and G201V) were evaluated
during and after MLN4924 treatment to determine the effect ofthese mutations on pathway activity recovery. Cells were
treated with MLN4924 10 mM for 1 hr, after which compound
was removed and replaced with drug-free media; cells were
harvested at 0 min, 15 min, 2 hr, or 5 hr postdrug washout
(Figure 6A). In agreement with previous observations (Brownell
et al., 2010), western blot analysis of wild-type cells indicated
incomplete recovery of NEDD8-cullin and NEDD8-UBC12
and a persistence of NEDD8-MLN4924 adduct levels at
both 1 mM and 10 mM for at least 5 hr postwashout. The pro-
longed pathway inhibition in the washout setting was corrobo-
rated by continued elevation of two CRL substrates, NRF2 and
CDT1. In contrast, both A171T and G201V mutant cell lines
showed almost-complete recovery of pathway activity as
early as 15 min postwashout (Figure 6A). Interestingly, it ap-
peared that the two mutant cell lines contained a reduced
amount of NEDD8-MLN4924 adduct compared to wild-type
cells, even though the levels of total NAEb appeared similar.
This would support the biochemical findings of a slower rate of
adduct formation and weaker binding of adduct in the mutant
enzymes.
To determine whether lower amounts of NEDD8-MLN4924
adduct were bound to NAEb, cells were treated under the
same washout conditions but subjected to immunoprecipitation
assays with NAEb (Figure 6B). Similar levels of NAEb and NAE1
were detected in immunoprecipitates, indicating that the NAE
heterodimer had been efficiently extracted from cell lysates.
Immunoprecipitates were next probed with the NEDD8-
MLN4924 antibody, which detected lower levels bound to
A171T and G201V mutants compared to the wild-type enzyme.
Lower levels of bound NEDD8-MLN4924 adduct in A171T and
G201V mutants compared to wild-type enzyme were confirmed
by running the 1 hr incubation samples on the same gel (Fig-
ure S7). It is likely that the amount of NEDD8-MLN4294 adduct
bound to NAEb is comprised mostly of an adduct bound to the
wild-type but not the mutant enzyme, as the mutant enzyme
can form an adduct but not bind the adduct tightly. To determine
if higher levels of unbound adduct were present in mutant versus
wild-type cells, the flow-through from the immunoprecipitates
was probed with the NEDD8-MLN4924 adduct antibody (Fig-
ure 6B). However, there did not appear to be a difference inCancer Cell 21, 388–401, March 20, 2012 ª2012 Elsevier Inc. 395
Figure 6. MLN4924-Resistant Cells with a Heterozygous NAEb Mutation Show Reduced Levels of NEDD8-MLN4924 Adduct Formation,
Faster Recovery of Pathway Inhibition, and Are More Sensitive to a Tighter-Binding NAE Inhibitor
(A) HCT-116WT, A171T, or G201V cells were treated withMLN4924 1 mMor 10 mM for 1 hr, the compound was washed out, and the cells were incubated in drug-
free media and harvested at the indicated times. Protein lysates were probed by western blotting for NEDD8-cullin, NEDD8-NAEb, NEDD8-UBC12, NEDD8-
MLN4924 adduct, CDT1, NRF2, and tubulin.
(B) Immunoprecipitation assays were performed with a NAEb antibody and resultant isolates probed with NAEb, NAE1, and NEDD8-MLN4924 adduct antibody.
Flow through from the immunoprecipitation assays was probed with NEDD8-MLN4924 adduct antibody. See also Figure S7.
(C) HCT-116WT, A171T, or G201V cells were treated with various concentrations of compound 1 for 4 hr, and protein lysates were probed by western blotting for
UBC10, ubiquitin K48 chains, NEDD8-cullin, NEDD8-NAEb, NEDD8-UBC12, CDT1, and a-tubulin.
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may be due to proteolysis of adduct when it is released from
NAEb in cells. These data show that, following inhibition of
mutant NAEb in cells, pathway activity recovers quickly and
correlates with lower amounts of NEDD8-MLN4924 adduct
bound to the enzyme.
The data in biochemical and cell-based assays would suggest
that a NEDD8-inhibitor adduct, which was able to bind more
tightly to the enzyme, may overcome resistance to MLN4924
treatment-emergent NAE mutations. To test this hypothesis we
used Compound 1, which in biochemical assays had faster rates
of enzyme inhibition and slower rates of recovery compared to
MLN4924. HCT-116 wild-type, and A171T and G201V mutant
cells were exposed to increasing concentrations of Compound
1 for 4 hr and assessed for pathway activity by western blotting
(Figure 6C). Since Compound 1 also inhibits UBA1, we could
show comparable inhibition of ubiquitination of Ubc10 (an E2
for ubiquitin) and polyubiquitination in all cells (Figure 6C).
In contrast to MLN4924 (see Figure 2), Compound 1 was able
to produce comparable inhibition of NAEb-NEDD8, NEDD8-
cullin, and NEDD8-UBC12 in G201V mutant versus wild-type
cells, and there was only a modest decrease in A171T mutant
cells compared to wild-type cells. This likely reflects the
quicker recovery of enzyme activity seen with Compound 1 in
A171T biochemical assays. These data suggest that NEDD8-
inhibitor compounds with improved binding affinities may over-
come the resistance observed in the NAEb mutations we
have identified. In addition, to provide complete inhibition of
the A171T mutation, alternative strategies may need to be em-
ployed, which could include the generation of covalent inhibitors
of the enzyme.
Sequencing of DNA from AML, Colon Cancer,
and Melanoma Tumor Samples Does Not Detect
Preexisting Mutations in NAEb
To determine whether mutations in NAEb could be detected in
cancer patients and therefore may exist prior to MLN4924
therapy, DNA from 50 colon cancer and melanoma tumor
samples and 41 AML samples were subjected to Sanger and
mass spectrometry-based (Sequenom platform) sequencing
(Table S4). No NAEbmutations were detected by either method,
with the Sequenom platform having a sensitivity limit of approx-
imately 10%. To increase the sensitivity of detection we sub-
jected 21 of the AML samples to next-generation sequencing
of NAEb using the illumina platform but did not detect any muta-
tions in NAEb. Similarly, ‘‘preexisiting’’ mutations in NAEb were
not detected in wild-type HCT-116, Calu-6, and NCI-H460 cells
by next-generation sequencing. Interestingly, one heterozygous
NAEb mutation (C249Y resulting from an amino acid change
G > A) has been reported in an ovarian cancer patient in the
Catalogue of Somatic Mutations in Cancer (Cosmic) database
(total 218 tumor samples tested; http://www.sanger.ac.uk/perl/
genetics/CGP/cosmic?action = bygene&ln = UBA3&start =
1&end = 1392&coords = AA%3Abp). This mutation is in a region
of NAEb that binds NAE1 (Walden et al., 2003) and so may inter-
fere with heterodimer formation and enzyme activity. Thus, we
were not able to detect a preexisting mutation in NAEb in DNA
isolated from patient tumors, leukemic blasts, or cancer cell
lines.DISCUSSION
MLN4924, a small-molecule inhibitor of an E1-activating enzyme
(NAE) that is being tested as a cancer therapy in humans, has
shown clinical activity with reports of complete responses
in patients with AML (Wang et al., 2011). In this report we
sought to characterize potential mechanisms of resistance to
MLN4924 in preclinical models of cancer. We demonstrated
that human tumor cell lines and xenografts grown in immuno-
compromised rodents can acquire resistance to MLN4924
through coding sequence mutations in NAEb. These studies
reveal a potential strategy for designing second-generation
inhibitors that could overcome resistance mediated by muta-
tions in NAEb.
The occurrence of amino acid substitutions has been
described as a common form of resistance for cancer drugs,
such as tyrosine kinase inhibitors, including imatinib, gefitinib,
and erlotinib (Shah et al., 2002; Kobayashi et al., 2005; Pao
et al., 2005). More recent examples include amino acid substitu-
tions in the anaplastic lymphoma kinase (ALK) following crizoti-
nib therapy that occurred in lung cancer patients harboring an
EML4-ALK translocation (Choi et al., 2010). Mutations in ALK
that reduced sensitivity to crizotinib were originally described
in preclinical studies using models of NPM-ALK translocations,
which led to the studies’ predictions that the mutations may
occur in EML4-ALK cancers (Lu et al., 2009). These data demon-
strate two important points: confirmation that the enzyme
targets of these drugs ‘‘drive’’ the cancer, and that the activity
of the inhibitors is through inhibition of the target. Furthermore,
these observations have led to treatment paradigms that include
retreating relapsed patients with a second-generation inhibitor
that can target enzymes with amino acid substitutions (Cortes
et al., 2011). This approach may be useful for NAEb amino acid
substitutions that are mechanisms of resistance to MLN4924 in
clinical studies.
Treatment-emergent mutations in NAEb were detected in the
ATP binding pocket and NEDD8 binding cleft with approximately
two-thirds at Alanine 171, representing a potential hotspot.
Though mutations in both areas generally led to changes in
affinities for ATP or NEDD8, this did not lead to a dramatic
change in catalytic rate of NAE (except in the case of A171D
and G201V). However, mutations in both areas of NAEb led to
a slower rate of enzyme inhibition and a NEDD8-MLN4924
adduct that was no longer tightly bound. We have previously
demonstrated that NEDD8-MLN4924 adduct formation is
necessary for potent NAE inhibition by MLN4924 and the tight
binding nature of the adduct is required for in vitro and cellular
potency (Brownell et al., 2010). In keeping with this notion, we
demonstrated reduced pathway inhibition in cells and a more
rapid recovery from compound inhibition in cell washout exper-
iments. We used a nonselective E1 inhibitor (Compound 1) to
probe the effects of more potent enzyme inhibition in vitro and
in cells. Compound 1 forms an adduct with NEDD8 in vitro
and shows a slower rate of recovery from enzyme inhibition
compared to MLN4924 in the wild-type and mutant enzymes
tested. These data indicate that the NEDD8-Compound 1
adduct is a tighter binder of wild-type andmutant NAEb enzymes
compared to MLN4924. Indeed, in A171T and G201V mutant
HCT-116 cells Compound 1 was able to more potently inhibitCancer Cell 21, 388–401, March 20, 2012 ª2012 Elsevier Inc. 397
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MLN4924. However, pathway inhibition in the A171T mutant
HCT-116 cells was less pronounced than in the G201V mutant
HCT-116 cells, which may indicate the need for a tighter binding
inhibitor or a molecule capable of covalent inactivation of the
A171T mutant. Nevertheless, these data support our notion
that a NAE-selective, NEDD8-compound adduct with high
affinity for mutant and wild-type enzymes should overcome
resistance in cells and tumor xenografts. Unfortunately, it was
not possible to test this in cell viability or xenograft experi-
ments, as Compound 1 is nonselective for other E1 enzymes
whose inhibition can result in viability effects (Brownell
et al., 2010). It will be of interest to complete a thorough charac-
terization of all NAEb mutants and the mechanism by which
they are conferring resistance to MLN4924. For example, the
Y228H mutation corresponds with a residue previously shown
to be important for ‘‘clamping’’ the C-terminus of NEDD8
into the adenylation domain, and the mutation of Y228 has
been previously shown to diminish NEDD8 adenylation
(Walden et al., 2003). This would suggest that this mutant
enzyme is inefficient for NEDD8-activation. In addition, themuta-
tion detected at C324Y is in a region of NAEb that may also
impact NEDD8 binding through structural perturbation of the
NEDD8 binding cleft (see Figure 5B). Interestingly, Alanine at
position 171 is conserved in most E1-activating enzymes,
including UBA1, UBA6, and Sumo-activating enzyme, suggest-
ing that selective inhibitors of these enzymes that are potential
drug targets may also be susceptible to the same resistance
mechanism.
The resistant cell lines were selected following a short
exposure (four days) to high concentrations of MLN4924. All
cell lines were isolated as clonal populations, shown to be resis-
tant to MLN4924 and still sensitive to other chemotherapies,
including proteasome inhibition (bortezomib), an anthracycline
(doxorubicin), and a topoisomerase I inhibitor (SN-38). Reverse
transcription-polymerase chain reaction analysis of the clones
indicated an elevation of drug efflux mechanisms with increased
detection of mRNA for Pgp and BCRP in some cell lines.
However, it appears that the elevation of drug efflux does not
significantly contribute to the resistance, as cotreating cells
with a number of Pgp, BCRP, and MRP2 inhibitors did not
sensitize cells to MLN4924 (dipyridamole, Shalinsky et al.,
1993; MK519, Gekeler et al., 1995; GF120918, Hyafil et al.,
1993; K0143, Allen et al., 2002; LY5979, Dantzig et al., 1996).
These data, in addition to the presence of mutations in NAEb,
indicate that the resistance is driven by mutations in the target
enzyme.
MLN4924 induces DNA damage in cells via re-replication
(Milhollen et al., 2011), and this mechanism of inducing hyperre-
plication of DNA may aid in the development of resistance
through increased random mutagenesis. HCT-116, H460, and
Calu-6 cells all undergo DNA re-replication, whereas OCI-Ly10
cells do not (Milhollen et al., 2010). We were able to detect an
NAEbmutation in the OCI-Ly10 model, suggesting that resistant
mutants can emerge irrespective of the mechanism of action of
MLN4924. Interestingly, HCT-116 cells have a deficiency in the
DNA mismatch repair protein MLH1 (Taverna et al., 2000), and
this may make them more susceptible to resistance mutations
by virtue of increased genomic instability. This assertion may398 Cancer Cell 21, 388–401, March 20, 2012 ª2012 Elsevier Inc.be supported by the increased number of mutations detected
in HCT-116 cell lines and xenografts compared to others used
in these studies that do not possess the same defect in DNA
repair. It will be of interest to understand whether themechanism
of DNA re-replication and/or defects in DNA repair make cells
more likely to develop resistance toMLN4924 throughmutations
in NAEb.
In these studies we have detected heterozygous mutations in
NAEb, where cells maintain one wild-type copy of NAEb. An
important model system to conclusively prove that mutations
in NAEb drive resistance would be an engineered cell line that
only expresses the mutant, not the wild-type, enzyme. Thus
far, we have not been successful in developing such a model
system. It is possible that a wild-type enzyme is required to
support growth and that the role of the mutant enzyme is to
enable NEDD8 conjugation when the wild-type enzyme is under
transient inhibition by MLN4924 in cells and xenografts. Since
the mutation frequency of NAEb in cell and xenograft popula-
tions is 50%, we developed mass spectrometry and next-
generation sequencing methodologies that allowed us to detect
NAEb mutations to a frequency of 0.5%. We were not able to
detect mutations in NAEb that were preexisting in the cell line,
xenograft, or patient tumor DNA samples, suggesting that the
mutations are acquired during the selection process. A search
of single-nucleotide polymorphism databases did not reveal
the existence of the mutations reported in human populations,
but we cannot rule out the possibility that mutations do exist at
a lower frequency than 0.5% in tumors. Indeed, a mutation in
NAEb has been reported in the Cosmic database in an ovarian
cancer sample at C249Y. This residue is in a region of NAEb
that is involved in binding NAE1 (Walden et al., 2003), and so it
is possible that this would interfere with heterodimer formation
and enzyme activity. It will be important to continue efforts to
establish whether mutations are preexisiting, as this may predict
patients who are more likely to relapse following MLN4924
administration.
These studies demonstrate that treatment-emergent muta-
tions in NAEb can confer resistance to MLN4924 in preclinical
models. Since NAEb mutations appear to be the most common
cause of resistance in our studies, irrespective of the cellular
outcome following NAE inhibition, this confirms the selectivity
of MLN4924 for its target. We did observe the regrowth of
THP-1 AML xenografts that did not contain a mutation in
NAEb, suggesting that other mechanisms of resistance to
MLN4924 are also likely to occur. Mechanisms of MLN4924
resistance will be explored further so that continued clinical
strategies can be employed in responding patients. These may
take the form of combination partners based on complimentary
biology in the context of NAE inhibition or next-generation
NAE inhibitors targeted to mutant NAEb that may emerge in
MLN4924-relapsed patients.
EXPERIMENTAL PROCEDURES
Materials
[32P]-PPi (Cat. No. NEX019), [a-32P]-ATP (Cat. No. BLU003H250UC), and
[a-32P]-ATP (Cat. No.BLU002250UC) were obtained from Perkin Elmer
(Boston, MA, USA). Other chemicals were purchased from Sigma-Aldrich
(St. Louis, MO, USA). N-terminal FLAG-tagged NEDD8 with the sequence of
N-MDYKDDDDK-NEDD8 was expressed and purified as described (Soucy
Cancer Cell
A Resistance Mechanism for NAE Inhibitionet al., 2009a). Untagged NEDD8 and N15- and C13-labeled, untagged NEDD8
(NEDD8*) was expressed and purified similarly. N-terminal GST-tagged
Ubc12 was expressed and purified as described (Soucy et al., 2009a). His-
tagged NAE proteins (NAE1 and His-tagged NAEb wild-type and mutants)
were cloned into Rosetta (DE3) cells and complexes were generated by co-
expression into Escherichia coli. Expressed proteins were purified by affinity
(Ni-NTA agarose; Qiagen, Valencia, CA, USA) or conventional chromatog-
raphy. GST-tagged NAE proteins (NAE1 and GST-tagged NAEb wild-type
and mutants) were generated by co-infection of Sf9 cells (Soucy et al.,
2009a). GST-NAE proteins were purified by affinity chromatography (Gluta-
thione Sepharose 4B; GE Healthcare, Piscataway, NJ, USA) followed by Hi-
Trap Q HP (GE Healthcare).
Cell Culture, Cell Viability, and Western Blot Analysis
Cell line cultures were maintained using the appropriate cell culture media as
recommended by ATCC and as previously reported (Soucy et al., 2009a;
Milhollen et al., 2010). To derive resistant cell lines HCT-116, Calu-6, and
NCI-H460 cells were incubated with high concentrations of MLN4924
(REC90 concentrations) for four days, after which the remaining cells were
removed, plated as single-cell clones, and cultured in drug-free media.
Cell viability assays were completed using a 96 hr ATPlite assay (Perkin
Elmer) as previously reported (Soucy et al., 2009a). Whole-cell extracts were
prepared and immunoblotting assays performed as previously described
(Soucy et al., 2009a) with primary antibodies as follows: CDT1, NRF2,
NEDD8, NAEb, UBC12, and MLN4924-NEDD8-ADS (MIL22; Millennium,
Cambridge, MA, USA); UBC10 (Boston Biochem, Cambridge, MA, USA); K48
(Millipore, Billerica, MA, USA); NAE1 (Sigma-Aldrich); and tubulin (Santa
Cruz, Santa Cruz, CA, USA). Secondary Alexa-680-labeled antibodies to
rabbit/mouse IgG (Molecular Probes, Grand Island, NY, USA) were used as
was appropriate, and blots were imaged using the Li-Cor Odyssey Infared
Imaging system.
Cell Culture Washout and Immunoprecipitation Analysis
HCT-116 wild-type, A171, and G201V cells were treated with either MLN4924
1 mM or 10 mM or DMSO for 1 hr. Cells were washed with media to remove the
drug, replaced with fresh media, and harvested at 0 hr, 0.25 hr, 2 hr, or 5 hr
postwashout. Lysates were prepared as previously reported (Soucy et al.,
2009a). Washout lysate (100 mg) was incubated with 5 mg NAEb antibody on
ice for 1 hr. Slurry Protein G agarose (Upstate, Billerica, MA, USA; 50 ml of
50%) was added and tumbled for 1 hr at 4C. Samples were spun down and
supernatant removed to fresh tube (unbound fraction), and beads were
washed three times with buffer. Sample buffer (50 ml 2X) was added to beads
(bound fraction), and samples were fractionated on sodium dodecyl sulfate
polyacrylamide gel electrophoresis gels and immunobloted as indicated. For
the unbound fraction, the above procedure was repeated using 2 mg
MLN4924-NEDD8-ADS (MIL22) antibody and 50 ml of 50% slurry Protein A
agarose (Pierce, Rockford, IL, USA).
Immunocompromised Rat and Mouse Antitumor Studies
Female NCr nude rats (Taconic Farms, Germantown, NY, USA), aged
6–8 weeks, were inoculated with 10 3 106. HCT-116 cells were subcutane-
ously injected in the right flank. Tumor growth was measured using digital
vernier calipers. When mean tumor growth reached 500 mm3, rats were as-
signed randomly to treatment groups and dosed subcutaneou sly with vehicle
(20% hydroxypropyl-beta-cyclodextrin) or MLN4924. Rats received one dose
per day twice-weekly for two weeks (days 1, 4, 8, and 11) of a 21-day therapy
cycle. After three cycles of treatment, refractory tumors were collected.
Female CB-17 SCID mice (Charles River Laboratories, Wilmington, MA,
USA), aged 6–8 weeks, were inoculated with 23 106 THP-1 or OCI-Ly10 cells
with Matrigel support (1:1, v/v). When mean tumor growth reached 200 mm3,
mice were assigned randomly to treatment groups and dosed subcutaneously
with vehicle (20% hydroxypropyl-beta-cyclodextrin) or MLN4924. Mice
received two doses per day twice-weekly (days 1, 4, 8, 11, 15, 18, 22, and
so on) until tumors reached 500–800 mm3. Tumors were then collected
and one 40 mg–50 mg piece of tumor was subcutaneously implanted using
a 13-gauge trocar needle into 6–8 naive animals for further study. In addition,
tumor DNA was extracted for mutational analysis as described in the Supple-
mental Experimental Procedures. All studies were done in accordance with thestandards of ethical treatment approved by the Institutional Animal Care and
Use Committee (IACUC) and Association for the Assessment and Accredita-
tion of Laboratory Animal Care (AAALAC). All animal experiments were
approved by the Institutional Animal Care and Use Committee of Millennium
Pharmaceuticals Inc.
Pharmacodynamic Marker Analysis
Mice and rats bearing HCT-116, THP-1, or OCI-Ly10 tumors were adminis-
tered a single MLN4924 dose, and at the indicated times, tumors were excised
and extracts prepared. The relative levels of NEDD8-cullin and pIkBa were
estimated by quantitative immunoblot analysis (Li-Cor Odyssey system)
using Alexa680-labeled anti-IgG (Molecular Probes) as the secondary anti-
body. For the analysis of CDT1 and cleaved caspase-3 levels in tumor
sections, formalin-fixed, paraffin-embedded tumor sections were stained
with the relevant antibodies, amplified with HRP-labeled secondary anti-
bodies, and detected with the ChromoMap DAB Kit (Ventana Medical
Systems, Tuscon, AZ, USA). Slides were counterstained with hematoxylin.
Images were captured using an Eclipse E800 microscope (Nikon Instruments,
Melville, NY, USA) and Retiga EXi color digital camera (QImaging, Surrey, BC,
Canada) and processed using Metamorph software (Molecular Devices,
Sunnyvale, CA, USA). CDT1 and cleaved caspase-3 are expressed as a func-
tion of the DAB signal area.
Measurement of NEDD8-MLN4924 Adduct Levels in Tumor
Xenografts
To quantify the absolute level of NEDD8-MLN4924 adduct in tumor xenografts,
30 mg total protein of each lysate sample was mixed with 0.1 pmol (0.9 ng)
NEDD8*-MLN4924 followed by NuPAGE Bis-Tris 4%–12% SDS gel separa-
tion (Invitrogen); NEDD8 gel fractions were excised and in-gel tryptic
digestion was performed as described previously (Brownell et al., 2010). The
digests were analyzed on an LC/MS/MS system (Brownell et al., 2010).
The NEDD8-MLN4924 adduct amount in each sample was calculated from
the ratio of the peak areas of Gly-Gly-MLN4924 to Gly*-Gly*-MLN4924 in the
chromatogram.
Biochemical Characterization of NAEb and Mutant Enzymes
Biochemical characterization and IC50 determinations were performed using
an improved pyrophosphate exchange assay developed by Bruzzese et al.
(2009). ATP-PPi exchange reactions were performed in buffer containing
50 mM HEPES (pH 7.5), 25 mM NaCl, 10 mM MgCl2, 0.05% BSA, 0.01%
Tween-20, and 1 mM DTT. NEDD8 titrations were performed by serial dilution
of NEDD8 into a 96-well assay plate containing 10 nM NAE, 1 mM ATP, and
0.2 mM PPi (50 cpm/pmol [32P] PPi). Assays were incubated for 30 min at
37C in a final volume of 50 ml and were stopped with the addition of 500 ml
of 5% (w/v) trichloroacetic acid containing 10 mM PPi. The quenched reac-
tions were transferred to a dot-blot apparatus fitted with activated charcoal
filter paper as described previously (Bruzzese et al., 2009). CPM was con-
verted to pM/min using an [a-P32] ATP standard curve. Since NEDD8 was
inhibitory at higher concentrations for wild-type and A171T/D NAEb, inhibited
top points for these particular mutants were excluded before fitting for an esti-
mated KM. All KMs were fit using the standard Michaelis-Menten equation for
enzyme kinetics. ATP KMs were determined by serial diluting ATP into a
96-well assay plate under similar assay conditions. Reactions were initiated
with addition of NEDD8 (0.16 mM for wild-type, A171T/D and 2.5 mM for
N209K, E204K, and G201V). Assays were incubated for 30 min at 37C. PPi
titrations were performed under similar conditions, except with serial dilution
of PPi instead and using 1 mM ATP.
IC50s were determines by serial dilution of each compound into a
96-well assay plate containing 5 nM NAE, 1 mM ATP, and 0.2 mM PPi
(50 cpm/pmol [32P] PPi). Reactions were initiated with addition of NEDD8
(0.16 mM for wild-type, A171T/D, and 2.5 mM for N209K, E204K, and
G201V). Assays were incubated for 60 min at 37C in a final volume of 50 ml
and were stopped as previously described.
The enzyme reversibility assay was run in the FLAG-NEDD8-GST-UBC12
HTRF transthiolation assay described previously (Soucy et al., 2009a; Brownell
et al., 2010). Final concentrations of each enzyme after dilution were 10 pM
wild-type NAEb, 12.5 pM A171T NAEb, 30 pM N209K NAEb, and 33 pM
E204K/G201V NAEb.Cancer Cell 21, 388–401, March 20, 2012 ª2012 Elsevier Inc. 399
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All human tumor samples were obtained from commercial vendors (Supple-
mental Experimental Procedures) and were de-identified prior to purchase
and analysis.
AML
Forty one unique malignant AML patient tumors (21 bone marrow aspirates
and 20 bone marrow mononuclear cells) were genotyped for mutations found
in preclinical models using the sequenom NAEb assays (Supplemental Exper-
imental Procedures), and the full gene was sequenced by an Illumina Next-
Generation sequencing assay. All samples were found to be wild-type for
NAEb. The AML tumors represented newly diagnosed and relapsed patients
with M1-M5 diagnosis classification. The blast tumor count ranged from 2%
to 94%. Matched peripheral blood mononuclear cells were also sequenced
and found to be wild-type.
Colon Cancer
A collection of 50 unique mucinous and sigmoidal colon adenocarcinomas
with representative histologies of poor, moderate, and well-differentiated
and 10% to 100% tumor per tissue were genotyped for mutations found in
preclinical models using the Sequenom NAEb assays, and the full gene was
sequenced by Sanger sequencing. All samples were found to be wild-type
for NAEb.
Melanoma
A collection of 25 unique epithelioid and spindle cell-type melanoma adeno-
carcinomas, ranging from 25% to 100% tumor per tissue, were genotyped
for mutations found in preclinical models using the Sequenom NAEb assays,
and the full gene was sequenced by Sanger sequencing. All samples were
found to be wild-type for NAEb.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, four tables, and Supple-
mental Experimental Procedures and can be found with this article online at
doi:10.1016/j.ccr.2012.02.009.
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